Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.63 |
| ▸ | PDE6C | P51160 | 3/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | PDE6A | P16499 | 1/20 | 0.42 |
| ▸ | PDE6G | P18545 | 1/20 | 0.42 |
| ▸ | PDE6B | P35913 | 1/20 | 0.42 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403430 | 0.84 | PDE5A (0.78) | PDE5APDE6CPDE3BPDE3A | |
| SCHEMBL7239860 | 0.84 | PDE5A (0.71) | PDE5APDE6CPDE3BPDE3A | |
| SCHEMBL6333014 | 0.83 | PDE5A (0.72) | PDE5APDE6CPDE3BPDE3A | |
| SCHEMBL6333001 | 0.83 | PDE5A (0.80) | PDE5APDE6CPDE3BPDE3APDE6D | |
| SCHEMBL7248270 | 0.83 | PDE5A (0.78) | PDE5APDE6C | |
| SCHEMBL7247373 | 0.82 | PDE5A (0.71) | PDE5APDE6C | |
| SCHEMBL5595647 | 0.82 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL5596504 | 0.81 | PDE5A (0.80) | PDE5APDE6CPDE3BPDE3A | |
| Trifluoroacetic Acid SCHEMBL6332627 | 0.81 | PDE5A (0.70) | PDE5APDE6C | |
| SCHEMBL7239340 | 0.81 | PDE5A (0.68) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | PDE5A 3645/4885PDE6C 4802/4885PDE3B 4085/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | PDE5A 3645/4885PDE6C 4802/4885PDE3B 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.